These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Gaucher disease, Fabry disease and mucopolysaccharidosis type I--how can the rheumatologist recognise these patients?]. Manger B; Menge E; Schaefer R; Haase C; Seidel J; Michels H Z Rheumatol; 2006 Feb; 65(1):32, 34-43. PubMed ID: 16467949 [TBL] [Abstract][Full Text] [Related]
3. Treatable lysosomal storage diseases in the advent of disease-specific therapy. Peters H; Ellaway C; Nicholls K; Reardon K; Szer J Intern Med J; 2020 Nov; 50 Suppl 4():5-27. PubMed ID: 33210402 [TBL] [Abstract][Full Text] [Related]
4. What should rheumatologists know about Gaucher disease and Fabry disease? Connecting the dots for an overview. Cordeiro RA; Rosa Neto NS; Giardini HAM Adv Rheumatol; 2024 Mar; 64(1):22. PubMed ID: 38520029 [TBL] [Abstract][Full Text] [Related]
5. [Multisystem lesions in orphan diseases: rheumatological aspects of Fabry's disease. Case report]. Mashkunova OV; Isabekova AH; Botabekova AZ; Novikov PI Ter Arkh; 2023 Aug; 95(6):505-510. PubMed ID: 38158971 [TBL] [Abstract][Full Text] [Related]
6. [How does the landscape change in lysosomal storage disease]. Parini R Pediatr Med Chir; 2007; 29(5):275-8. PubMed ID: 18402399 [No Abstract] [Full Text] [Related]
7. Simplified newborn screening protocol for lysosomal storage disorders. Metz TF; Mechtler TP; Orsini JJ; Martin M; Shushan B; Herman JL; Ratschmann R; Item CB; Streubel B; Herkner KR; Kasper DC Clin Chem; 2011 Sep; 57(9):1286-94. PubMed ID: 21771947 [TBL] [Abstract][Full Text] [Related]
8. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. Hopkins PV; Campbell C; Klug T; Rogers S; Raburn-Miller J; Kiesling J J Pediatr; 2015 Jan; 166(1):172-7. PubMed ID: 25444528 [TBL] [Abstract][Full Text] [Related]
9. [Lysosomal storage diseases]. Manger B Z Rheumatol; 2010 Aug; 69(6):527-38. PubMed ID: 20532791 [TBL] [Abstract][Full Text] [Related]
10. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients. Rosa Neto NS; Bento JCB; Pereira RMR Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047 [TBL] [Abstract][Full Text] [Related]
11. The patient journey of patients with Fabry disease, Gaucher disease and Mucopolysaccharidosis type II: A German-wide telephone survey. Mengel E; Gaedeke J; Gothe H; Krupka S; Lachmann A; Reinke J; Ohlmeier C PLoS One; 2020; 15(12):e0244279. PubMed ID: 33382737 [TBL] [Abstract][Full Text] [Related]
12. Reference values for lysosomal enzymes activities using dried blood spots samples - a Brazilian experience. Müller KB; Rodrigues MD; Pereira VG; Martins AM; D'Almeida V Diagn Pathol; 2010 Sep; 5():65. PubMed ID: 20920262 [TBL] [Abstract][Full Text] [Related]
13. Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Pastores GM; Meere PA Curr Opin Rheumatol; 2005 Jan; 17(1):70-8. PubMed ID: 15604908 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic challenges and new therapies for rare lysosomal storage diseases. Hesselgrave B Case Manager; 2003; 14(6):48-52. PubMed ID: 14618149 [No Abstract] [Full Text] [Related]
15. Lysosomal storage disorders: Novel and frequent pathogenic variants in a large cohort of Indian patients of Pompe, Fabry, Gaucher and Hurler disease. Thomas DC; Sharma S; Puri RD; Verma IC; Verma J Clin Biochem; 2021 Mar; 89():14-37. PubMed ID: 33301762 [TBL] [Abstract][Full Text] [Related]
16. Treating lysosomal storage disorders: What have we learnt? Lachmann RH J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601 [TBL] [Abstract][Full Text] [Related]